{"id":"07e1fa8e-c74b-5cab-a90f-f4cb7bd56d11","stable_key":"09b23d0d-35e2-51ff-b1aa-b4f9227e4fa2:isoleucine-phenylbutyrate-kinase","predicate":"inhibits_tested","statement":"Phenylbutyrate inhibited recombinant BCKDH kinase, reduced E1-alpha phosphorylation and increased overall BCKDH activity in the reported assays.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"de8f80d9-45f0-52c9-a60e-e97bdfaafec9","mechanism_event_label":"A medicine can remove the brake on BCAA breakdown.","subject":{"id":"59e582c7-8a5b-5bc0-900d-42eb6c0e30be","slug":"sodium-phenylbutyrate","display_name":"Sodium phenylbutyrate","entity_type_key":"drug"},"object":{"id":"268544a3-0ad4-5ef5-a95d-04cfb1d8387c","slug":"bckdk-recombinant-assay","display_name":"Recombinant BCKDH-kinase preparation, species unresolved in accessed abstract","entity_type_key":"protein"},"evidence_count":1,"mechanism_event":{"id":"de8f80d9-45f0-52c9-a60e-e97bdfaafec9","stable_key":"09b23d0d-35e2-51ff-b1aa-b4f9227e4fa2:isoleucine-phenylbutyrate-kinase-event","event_type":"observed_relationship","label":"A medicine can remove the brake on BCAA breakdown.","description":"Phenylbutyrate inhibited recombinant BCKDH kinase, reduced E1-alpha phosphorylation and increased overall BCKDH activity in the reported assays.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"59e582c7-8a5b-5bc0-900d-42eb6c0e30be","slug":"sodium-phenylbutyrate","display_name":"Sodium phenylbutyrate","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"268544a3-0ad4-5ef5-a95d-04cfb1d8387c","slug":"bckdk-recombinant-assay","display_name":"Recombinant BCKDH-kinase preparation, species unresolved in accessed abstract","entity_type_key":"protein"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"c85b327e-f132-5d9a-8e4b-c2976fcc0373","slug":"isoleucine","display_name":"L-Isoleucine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"f77ac9db-cdaf-5b43-a2bc-a5a54e2aa26c","slug":"human-bckdh-complex","display_name":"Human branched-chain alpha-ketoacid dehydrogenase complex","entity_type_key":"protein_complex"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"f707c753-cc8c-5f06-90be-bb3d73c60a18","slug":"leucine","display_name":"L-Leucine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""},{"entity":{"id":"ae40617e-3df7-5d48-8dd2-f16a0d3a8a25","slug":"valine","display_name":"L-Valine","entity_type_key":"small_molecule"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":5,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary abstract","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Recombinant enzyme assays with supporting cellular/in-vivo experiments.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Protein species is not inferred from the patient part of the paper; activity responses varied among disease samples.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"L-Isoleucine collection; species, compartment, exposure, co-substrates and manipulation remain explicit.","comparator":null,"unit":null,"notes":"","entity":{"slug":"isoleucine","display_name":"L-Isoleucine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"A medicine can remove the brake on BCAA breakdown.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Phenylbutyrate therapy for maple syrup urine disease. · 2011 · https://pubmed.ncbi.nlm.nih.gov/21098507/ · DOI 10.1093/hmg/ddq507","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"3b859677-4fa6-5b81-ad67-f1bd80123cba","evidence_kind":"source_excerpt","locator":"Lines 298-304","start_line":298,"end_line":304,"excerpt":"## isoleucine-phenylbutyrate-kinase\nA medicine can remove the brake on BCAA breakdown.\nPhenylbutyrate inhibited recombinant BCKDH kinase, reduced E1-alpha phosphorylation and increased overall BCKDH activity in the reported assays.\nModel: Recombinant enzyme assays with supporting cellular/in-vivo experiments.\nLimitations: Protein species is not inferred from the patient part of the paper; activity responses varied among disease samples.\nEvidence access: Primary abstract\nPhenylbutyrate therapy for maple syrup urine disease. · 2011 · https://pubmed.ncbi.nlm.nih.gov/21098507/ · DOI 10.1093/hmg/ddq507","model_system":"Recombinant enzyme assays with supporting cellular/in-vivo experiments.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Original curation paraphrase; evidence access and experimental limitations specified.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"4b00f118-00fd-5cef-be97-13125eb958e9","stable_key":"import-09b23d0d-35e2-51ff-b1aa-b4f9227e4fa2","title":"L-Isoleucine: transport, translation, catabolism and cross-nutrient mechanisms (2026-09-19)","document_type":"imported_text","citation_label":"AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text.","file_path":"","sha256":"2058ff0da379586994e7fda6ae0086c60fa3173542bfaf1fb3871ad3e09f9c6c","revision_id":"f32192d4-9913-5d35-acbc-cf90ff17995e","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}